{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:30:57Z","timestamp":1793500257775,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.diagmicrobio.2009.11.009","type":"journal-article","created":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T04:56:13Z","timestamp":1268283373000},"page":"407-418","source":"Crossref","is-referenced-by-count":11,"title":["In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections"],"prefix":"10.1016","volume":"66","author":[{"given":"Peter J.","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Ruzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Tuckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Hal","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.diagmicrobio.2009.11.009_bib1","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 5","key":"10.1016\/j.diagmicrobio.2009.11.009_bib2","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections","volume":"41","author":"Bradford","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib3","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1469-0691.2008.02063.x","article-title":"In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community acquired pneumonia","volume":"14","author":"Bradford","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib4","volume":"Vol. 26","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib5","volume":"Vol. 27","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib6","volume":"Vol. 29","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib7","volume":"Vol. 29","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib9","series-title":"Abstr. L-1450. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Integrated results of 2 phase 3 studies comparing tigecycline (TGC) with levofloxacin (LEV) in patients (Pts) with community-acquired pneumonia (CAP)","author":"Dukart","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1469-0691.2000.00034-6.x","article-title":"In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline","volume":"6","author":"Edlund","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"issue":"Suppl. 5","key":"10.1016\/j.diagmicrobio.2009.11.009_bib11","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of two double-blind phase 3 comparison studies with vancomycin\/aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000\u20132004)","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib13","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.48.3.1034-1036.2004","article-title":"In vitro activities of tigecycline against the Bacteroides fragilis group","volume":"48","author":"Jacobus","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1358\/dot.2005.41.10.937460","article-title":"Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic","volume":"41","author":"Jones","year":"2005","journal-title":"Drugs Today"},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1128\/AAC.50.2.505-510.2006","article-title":"Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections","volume":"50","author":"Jones","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/187152108783954650","article-title":"Genetic determinants of tetracycline resistance and their effect on tetracycline and glycylcycline antibiotics","volume":"7","author":"Jones","year":"2008","journal-title":"Anti-Infect. Agents Med. Chem."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/AAC.00883-08","article-title":"Characterization and sequence analysis of extended-spectrum-{beta}-lactamase\u2013encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials","volume":"53","author":"Jones","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib18","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.45.9.2604-2608.2001","volume":"45","author":"Kenny","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib19","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1086\/424846","article-title":"Diagnosis and treatment of diabetic foot infections","volume":"39","author":"Lipsky","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib20","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01499-05","article-title":"Functional, biophysical, and structural bases for antibacterial activity of tigecycline","volume":"50","author":"Olson","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib21","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1128\/AAC.49.9.3910-3918.2005","article-title":"Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates","volume":"49","author":"Petersen","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and In vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/jac\/dki171","article-title":"Efflux-mediated antimicrobial resistance","volume":"56","author":"Poole","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib24","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jac\/dkm310","article-title":"Antimicrobial susceptibility among organisms from the Asia\/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.","volume":"60","author":"Reinert","year":"2007","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0924-8579(00)00198-9","article-title":"In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis","volume":"16","author":"Roblin","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/AAC.49.3.1017-1022.2005","article-title":"Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2005.05.005","article-title":"Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.patbio.2007.07.003","article-title":"In vitro activity of tigecycline against strains isolated from diabetic foot ulcers","volume":"55","author":"Sotto","year":"2007","journal-title":"Pathol. Biol. (Paris)"},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0960-894X(99)00216-4","article-title":"Synthesis and structure\u2013activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936","volume":"9","author":"Sum","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1469-0691.2005.01279.x","article-title":"Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers","volume":"12","author":"Tentolouris","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib31","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1128\/AAC.00625-07","article-title":"Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline","volume":"51","author":"Tuckman","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/AAC.47.2.665-669.2003","article-title":"AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis","volume":"47","author":"Visalli","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.11.009_bib33","series-title":"Tygacil\u2122 [package insert]","author":"Wyeth Pharmaceuticals","year":"2005"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889309004714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889309004714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T18:12:56Z","timestamp":1558894376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889309004714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0732889309004714"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.11.009","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}